Amarin Corporation plc

Amarin Corporation plc is a pharmaceutical company that develops and sells treatments to improve heart health and reduce cardiovascular risk. The company's main product is VASCEPA (icosapent ethyl). VASCEPA was initially approved by the U.S. Food and Drug Administration (FDA) in July 2012. This initial approval was for use alongside diet to lower triglyceride levels in adult patients with severe hypertriglyceridemia, defined as levels of 500 mg/dL or higher (known as the MARINE indication). On December 13, 2019, the U.S. FDA expanded VASCEPA's approved uses based on findings from the REDUCE-IT trial. VASCEPA is now also approved by the U.S. FDA for use with maximally tolerated statin therapy to reduce ongoing cardiovascular risk in specific high-risk patients (known as the REDUCE-IT indication). Amarin Corporation plc is incorporated under the laws of England and Wales. Its principal office is in Dublin, Ireland, and its registered office is in London, England. The company's primary office in the United States is located in Bridgewater, NJ.